Effect of Evolocumab on Coronary Plaque Composition.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of the American College of Cardiology"
DOI: 10.1016/j.jacc.2018.06.078
Abstract: BACKGROUND Incremental low-density lipoprotein (LDL) cholesterol lowering with the proprotein convertase subtilisin kexin type 9 inhibitor evolocumab regresses coronary atherosclerosis in statin-treated patients. OBJECTIVES The purpose of this study was to evaluate the effect of… read more here.
Keywords: mm3 mm3; evolocumab; plaque composition; plaque ... See more keywords
Cost-effectiveness of Evolocumab.
Sign Up to like & getrecommendations! Published in 2018 at "Revista espanola de cardiologia"
DOI: 10.1016/j.rec.2018.04.028
Abstract: In recent decades, heart disease patient care has improvednotably, largely due to constant treatment innovations. However, when it comes to evaluating the introduction of any new medication into clinical practice, it is important not only… read more here.
Keywords: treatment; cost; study; evolocumab ... See more keywords
GREATER LIKELIHOOD OF REGRESSION OF CORONARY ATHEROSCLEROSIS WITH THE PCSK9 INHIBITOR, EVOLOCUMAB, IN PATIENTS WITH HIGHER LP(A) LEVELS
Sign Up to like & getrecommendations! Published in 2018 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(18)30558-8
Abstract: There is genetic and epidemiological evidence demonstrating the association between Lp(a) levels and cardiovascular disease. While evolocumab reduces Lp(a) by 25-30%, the impact of PCSK9 inhibition on plaque at different Lp(a) levels is unknown. GLAGOV… read more here.
Keywords: regression coronary; greater likelihood; pcsk9 inhibitor; likelihood regression ... See more keywords
CONSISTENCY OF LDL-C REDUCTION WITH EVOLOCUMAB: AN ANALYSIS FROM FOURIER
Sign Up to like & getrecommendations! Published in 2018 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(18)32268-x
Abstract: Questions have been raised about interpatient variability in response to PCSK9 inhibitors. FOURIER was a randomized, pbo-controlled trial of the PCSK9i evolocumab, a fully human mAb, in pts w/ ASCVD on a statin. We examined… read more here.
Keywords: consistency ldl; reduction evolocumab; ldl reduction; evolocumab ... See more keywords
P654Effectiveness of evolocumab for patients with familial hypercholesteraemia (FH) in European clinical practice
Sign Up to like & getrecommendations! Published in 2019 at "European Heart Journal"
DOI: 10.1093/eurheartj/ehz747.0261
Abstract: FH is a genetic disorder which causes lifelong elevations in LDL-C from birth, resulting in a significantly increased risk of premature atherosclerotic cardiovascular disease (ASCVD). In clinical trials among patients with heterozygous FH (HeFH) and… read more here.
Keywords: clinical practice; ldl; evolocumab; hefh hofh ... See more keywords
Restoring mortality data in the FOURIER cardiovascular outcomes trial of evolocumab in patients with cardiovascular disease: a reanalysis based on regulatory data
Sign Up to like & getrecommendations! Published in 2022 at "BMJ Open"
DOI: 10.1136/bmjopen-2021-060172
Abstract: Objective The FOURIER trial showed a benefit of the PCSK9 inhibitor evolocumab over placebo with respect to cardiovascular outcomes in patients with cardiovascular disease. However, we observed some inconsistencies between the information in the Clinical… read more here.
Keywords: cardiovascular disease; trial; group; evolocumab ... See more keywords
Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease
Sign Up to like & getrecommendations! Published in 2022 at "Circulation"
DOI: 10.1161/circulationaha.122.061620
Abstract: Background: In FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk), the proprotein convertase subtilisin-kexin type 9 inhibitor evolocumab reduced low-density lipoprotein cholesterol (LDL-C) and risk of cardiovascular events and was… read more here.
Keywords: long term; evolocumab; risk; parent ... See more keywords
No association between APOE genotype and lipid lowering with cognitive function in a randomized controlled trial of evolocumab
Sign Up to like & getrecommendations! Published in 2022 at "PLoS ONE"
DOI: 10.1371/journal.pone.0266615
Abstract: APOE encodes a cholesterol transporter, and the ε4 allele is associated with higher circulating cholesterol levels, ß-amyloid burden, and risk of Alzheimer’s disease. Prior studies demonstrated no significant differences in objective or subjective cognitive function… read more here.
Keywords: cognitive function; apoe genotype; trial; genotype ... See more keywords